Contract Development Manufacturing Organization (CDMO) Market Insights, Competitive Landscape, and Market Forecast - 2034

Contract Development Manufacturing Organization (CDMO) Market Summary

• The global contract development manufacturing organization (CDMO) market is expected to increase from USD 233.71 billion in 2025 to USD 407.09 billion by 2034, reflecting strong and sustained growth.
• The global contract development manufacturing organization (CDMO) market is growing at a CAGR of 7.25% during the forecast period from 2026 to 2034.
• The growth of the global contract development and manufacturing organization (CDMO) market is driven by the rising prevalence of chronic diseases, the rapid expansion of biologics and biosimilar production, and increasing strategic collaborations and mergers among key players. The growing burden of conditions such as cancer, diabetes, and cardiovascular disorders is prompting pharmaceutical and biotechnology companies to outsource drug development and manufacturing to CDMOs for their expertise, scalability, and cost efficiency. Meanwhile, the surge in biologics and biosimilars is creating new opportunities for CDMOs with advanced bioprocessing and regulatory capabilities. Additionally, ongoing partnerships and M&A activities are enabling companies to expand service offerings, strengthen global presence, and enhance technological competitiveness, fostering a more integrated and innovation-driven CDMO market.
• The leading companies operating in the contract development manufacturing organization (CDMO) market include Catalent Inc., Thermo Fisher Scientific Inc., The Lubrizol Corporation, Recipharm (EQT), Cambrex Corporation, Merck & Co. Inc., AGC Biologics, Nerpharma S.r.l., Danaher Corporation, EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Revvity Inc., WuXi Biologics, Laboratoire Elaiapharm, and others.
• North America is expected to dominate the overall contract development manufacturing organization market due to the strong pharmaceutical innovation, advanced biotechnology infrastructure, and a well-established regulatory environment. The region's growing burden of chronic diseases such as cancer and cardiovascular disorders is fueling demand for complex therapeutics, prompting greater outsourcing of drug development and manufacturing to specialized CDMOs. Continuous investments in biologics, biosimilars, and advanced manufacturing technologies, along with a surge in personalized medicine initiatives, are further strengthening market growth. Supported by robust R&D capabilities, favorable FDA regulations, and active collaborations among industry players.
• In the drug type segment of the contract development manufacturing organization (CDMO) market, the small molecules category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Contract Development Manufacturing Organization (CDMO) Market

• Increasing prevalence of chronic diseases leading to a surge in contract development manufacturing organization: The rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, neurological conditions, and autoimmune diseases is significantly driving the growth of the contract development and manufacturing organization (CDMO) market. The growing burden of these long-term health conditions has intensified the demand for complex, targeted, and personalized therapeutics. As pharmaceutical and biotechnology companies face increasing pressure to accelerate drug development while managing costs, they are increasingly outsourcing research, development, and manufacturing activities to CDMOs. These organizations offer specialized expertise, advanced manufacturing technologies, and regulatory experience that enable faster product development and commercialization. Consequently, the increasing incidence of chronic illnesses is directly boosting the need for outsourcing solutions, positioning CDMOs as crucial partners in addressing global healthcare challenges.
• Expansion in biologics and biosimilar production: The rapid expansion of biologics and biosimilar production has emerged as a key growth catalyst for the CDMO market. Biologics, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies, are highly complex to develop and manufacture, requiring sophisticated bioprocessing facilities and technical expertise. Many pharmaceutical companies lack the infrastructure or resources to manage such large-scale biologics production in-house, leading to increased reliance on CDMOs with specialized capabilities in cell culture systems, bioreactor operations, and analytical testing. Similarly, the rising adoption of biosimilars following the patent expiration of several blockbuster biologic drugs has opened new outsourcing opportunities. CDMOs are investing heavily in state-of-the-art biologics manufacturing platforms, single-use technologies, and flexible production systems to meet this growing demand, thereby solidifying their role in the biologics and biosimilar value chain.
• Extensive strategic collaborations and merger & acquisition (m&a) initiatives among key market players: Strategic collaborations, partnerships, and mergers and acquisitions (M&A) among leading CDMOs and pharmaceutical companies are playing a pivotal role in shaping the industry's growth trajectory. These initiatives enable companies to expand service portfolios, enhance technological capabilities, and strengthen global manufacturing footprints. M&A activities allow large CDMOs to acquire niche expertise, specialized technologies, or regional presence, helping them deliver comprehensive, end-to-end solutions to their clients. Collaborative partnerships, on the other hand, promote innovation by integrating complementary strengths, such as combining formulation expertise with advanced delivery systems or leveraging AI-driven process optimization. Such strategic initiatives not only enhance operational efficiency but also create economies of scale, enabling CDMOs to offer competitive pricing and faster turnaround times. Collectively, these efforts are fostering a more integrated, technologically advanced, and globally connected CDMO market ecosystem.

Contract Development Manufacturing Organization (CDMO) Market Report Segmentation

This Contract Development Manufacturing Organization (CDMO) Market report offers a comprehensive overview of the global Contract Development Manufacturing Organization (CDMO) Market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Drug Type (Small Molecules and Biologics), Service Type (Active Pharmaceutical Ingredient (API) and Finished Drug Product), Forms (Solids and Liquids), Manufacturing (Clinical Manufacturing and Commercial Manufacturing), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Contract Development Manufacturing Organization (CDMO) Market.

A contract development and manufacturing organization (CDMO) is a company that provides comprehensive services to pharmaceutical and biotechnology firms for the development and manufacturing of drugs. CDMOs support clients from early-stage formulation and process development to large-scale commercial production, offering expertise in areas such as analytical testing, regulatory compliance, and supply chain management. By outsourcing to CDMOs, companies can accelerate product development, reduce costs, and focus on core competencies like research and marketing.

The growth of the contract development and manufacturing organization (CDMO) market is being strongly propelled by several key factors, including the increasing prevalence of chronic diseases, the rapid expansion of biologics and biosimilar production, and extensive strategic collaborations and merger and acquisition (M&A) initiatives among key industry players. The rising global burden of chronic conditions such as cancer, diabetes, cardiovascular diseases, and autoimmune diseases has accelerated the demand for innovative and specialized therapeutics, prompting pharmaceutical and biotechnology companies to increasingly outsource drug development and manufacturing processes to CDMOs for their technical expertise, scalability, and cost efficiency.

Simultaneously, the surge in biologics and biosimilar production is creating new opportunities for CDMOs equipped with advanced bioprocessing capabilities, single-use technologies, and regulatory proficiency, as these complex products require specialized infrastructure and precision-driven manufacturing approaches. In addition, the market is witnessing a wave of strategic collaborations, partnerships, and M&A activities that are enabling CDMOs to expand service portfolios, strengthen global footprints, and enhance technological competitiveness. Collectively, these factors are driving the evolution of a more integrated, innovation-driven, and resilient CDMO market, positioning it as an indispensable partner in the modern pharmaceutical and biopharmaceutical value chain.

What are the latest Contract Development Manufacturing Organization (CDMO) Market dynamics and trends?

The global contract development and manufacturing organization (CDMO) market has experienced substantial growth in recent years, driven by the rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular, and neurological disorders, which are increasing the demand for complex and specialized therapeutics. In response, pharmaceutical and biotechnology companies are expanding their outsourcing activities to CDMOs to access advanced technological capabilities, regulatory expertise, and cost-efficient development solutions. Furthermore, the rapid expansion of biologics and biosimilar production has created strong demand for CDMOs with specialized bioprocessing infrastructure and expertise in large-molecule manufacturing. The market is also being shaped by extensive R&D investments, technological advancements such as AI-driven process optimization and continuous manufacturing, and a surge in strategic collaborations and mergers among leading players to enhance global presence and service integration.

Contract Development Manufacturing Organization (CDMO) Market Segment Analysis

Contract Development Manufacturing Organization (CDMO) Market by Drug Type (Small Molecules and Biologics), Service Type (Active Pharmaceutical Ingredient (API) and Finished Drug Product), Forms (Solids and Liquids), Manufacturing (Clinical Manufacturing and Commercial Manufacturing), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Contract Development Manufacturing Organization (CDMO) Market Regional Analysis

North America Contract Development Manufacturing Organization (CDMO) Market Trends

North America is expected to account for the highest proportion of the CDMO market in 2025, with a market share of 39%, out of all regions, supported by the convergence of robust pharmaceutical innovation, strong biotechnology infrastructure, and extensive strategic collaborations. The country's well-established ecosystem of drug developers, combined with continuous investments in biologics, cell and gene therapies, and advanced manufacturing technologies, is generating significant market momentum.

The growing burden of chronic diseases such as cancer, cardiovascular disorders, and infectious diseases continues to accelerate demand for innovative therapies, thereby increasing the need for specialized CDMO services across drug development and production stages.

According to the GLOBOCAN (2024), the U.S. faces a rapidly rising prevalence of chronic and rare diseases, with cancer alone projected to reach approximately 2.54 million new cases in 2025, increasing to 3.38 million by 2045.

This growing disease burden is driving pharmaceutical and biotechnology companies to expand their pipelines of biologics, biosimilars, and targeted therapies, many of which require sophisticated manufacturing capabilities provided by CDMOs. Moreover, the increasing complexity of drug formulations and the growing emphasis on personalized medicine have further strengthened the role of CDMOs as essential partners in scaling production efficiently while maintaining regulatory compliance.

The region also benefits from a highly advanced R&D environment supported by leading academic institutions, regulatory clarity from the FDA, and extensive venture capital funding. These factors collectively foster innovation and outsourcing trends, particularly among small and mid-sized biotech firms that rely on CDMOs for early-stage development, clinical trial manufacturing, and commercial production. The demand for biologics manufacturing, including monoclonal antibodies, recombinant proteins, and gene therapies, continues to expand rapidly, pushing CDMOs to enhance their technical capabilities and production capacity to meet growing client requirements.

Furthermore, the increase in strategic activities among key market players is further accelerating CDMO market growth across the region. For instance, in December 2024, Lonza announced its decision to exit the capsules and health ingredients business to focus exclusively on its core CDMO operations. Beginning in Q2 2025, the company plans to restructure into three business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. This strategic shift is aimed at reinforcing Lonza's leadership in high-value therapeutic areas, optimizing its operational efficiency, and advancing next-generation manufacturing technologies.

Therefore, the combination of an expanding biopharmaceutical pipeline, rising prevalence of chronic diseases, and a strong innovation-driven healthcare ecosystem positions the region as a global leader in the CDMO market. The region's dominance is further bolstered by continuous investments, regulatory support, and strategic corporate realignments, which together ensure sustained market expansion from 2026 to 2034 and beyond.

Europe Contract Development Manufacturing Organization (CDMO) Market Trends

Europe represents another major hub in the global CDMO market, driven by its strong pharmaceutical base, expanding biologics and biosimilars sector, and well-established regulatory and quality frameworks. The region benefits from the presence of leading CDMOs in countries such as Switzerland, Germany, the U.K., and Ireland, which are recognized for their advanced manufacturing capabilities and expertise in high-value APIs, sterile injectables, and complex formulations. Growing emphasis on cost efficiency, regulatory compliance under EMA standards, and increased outsourcing by small and mid-sized biotech firms are fueling market growth across the continent. Moreover, the region's focus on digitalization, automation, and sustainability in pharmaceutical manufacturing is driving technological innovation among CDMOs. Strategic collaborations, capacity expansions, and the adoption of continuous manufacturing processes are further enhancing Europe's competitiveness, positioning it as a key region for integrated drug development and large-scale commercial production in the global CDMO landscape.

Asia-Pacific Contract Development Manufacturing Organization (CDMO) Market Trends

The Asia-Pacific region is emerging as one of the fastest-growing markets for contract development and manufacturing organizations (CDMOs), fueled by expanding pharmaceutical production, cost advantages, and increasing investments in advanced manufacturing infrastructure. Countries such as China, India, South Korea, and Japan are at the forefront of this growth, offering strong capabilities in small-molecule API manufacturing, biologics production, and formulation development. The region's favorable regulatory reforms, growing pool of skilled professionals, and government support for local biotech innovation have further strengthened its position as a global outsourcing destination. Moreover, multinational pharmaceutical companies are increasingly partnering with Asia-Pacific CDMOs to leverage lower production costs, shorter turnaround times, and scalable operations. The rapid digitalization of manufacturing, adoption of continuous and single-use technologies, and establishment of new GMP-compliant facilities are enhancing operational efficiency and global competitiveness. Collectively, these developments are transforming Asia-Pacific into a strategic hub for end-to-end CDMO services, driving sustained market expansion over the forecast period.

Who are the major players in the Contract Development Manufacturing Organization (CDMO) Market?

The following are the leading companies in the Contract Development Manufacturing Organization (CDMO) Market. These companies collectively hold the largest market share and dictate industry trends.

• Catalent Inc.
• Thermo Fisher Scientific Inc.
• The Lubrizol Corporation
• Recipharm (EQT)
• Cambrex Corporation
• Merck & Co. Inc.
• AGC Biologics
• Nerpharma S.r.l.
• Danaher Corporation
• EMERGENT
• Onyx Scientific Limited
• Lonza
• Siegfried Holding AG
• CordenPharma International
• FUJIFILM Diosynth Biotechnologies
• Samsung Biologics
• Delpharm
• Revvity Inc.
• WuXi Biologics
• Laboratoire Elaiapharm
• Others

How is the competitive landscape shaping the Contract Development Manufacturing Organization (CDMO) Market?

The competitive landscape of the Contract Development and Manufacturing Organization (CDMO) market is evolving rapidly, driven by strategic collaborations, mergers and acquisitions, and the adoption of advanced technologies aimed at enhancing service capabilities. Leading players are increasingly focusing on providing end-to-end integrated solutions that encompass drug discovery, formulation, clinical trial support, and commercial manufacturing to meet the rising demand for seamless outsourcing among pharmaceutical and biotechnology companies. Mid-sized CDMOs are differentiating themselves through niche expertise in biologics, cell and gene therapy, and highly potent active pharmaceutical ingredients (HPAPIs), while larger firms are expanding their global presence and technological infrastructure to secure long-term partnerships with major drug developers.

Additionally, companies are investing in capacity expansion and regional diversification to strengthen supply chain resilience and optimize production efficiency. With innovation, scalability, and regulatory compliance emerging as key determinants of success, the market dynamics are fostering both consolidation and specialization among participants. Overall, the global CDMO market remains moderately concentrated, with a few dominant firms holding substantial market share while numerous specialized and regional players continue to enrich its competitive landscape.

Recent Developmental Activities in the Contract Development Manufacturing Organization (CDMO) Market

• In May 2025, Lupin Manufacturing Solutions (LMS) announced the relegation of its core assets and long-term vision to capitalize on emerging opportunities in the CDMO space. By investing in innovative treatment platforms and harnessing the strength of India's robust API ecosystem, LMS aimed to enhance its capabilities and drive sustainable growth in the global contract development and manufacturing market.
• In May 2025, VGXI, Inc., a CDMO specializing in plasmid DNA for gene therapies and vaccines, completed a US FDA inspection at its GMP facility, leading to approval of a client's Biologics License Application (BLA). This milestone highlights VGXI's commitment to quality and regulatory excellence.
• In May 2025, Tivic Health(R) Systems, Inc. announced a definitive agreement with Scorpius BioManufacturing to complete GMP manufacturing validation of Entolimod(TM), its lead TLR5 candidate for Acute Radiation Syndrome (ARS), in preparation for a BLA filing with the FDA.
• In March 2025, Ayrmid Pharma Ltd. and RoslinCT announced plans to form a strategic partnership for the production of Omisirge, a cell therapy used to treat hematologic malignancies and commercialized in the U.S. by Ayrmid's subsidiary, Gamida Cell Inc.

Contract Development Manufacturing Organization (CDMO) Market Segmentation

• Medical Device Contract Manufacturing by Drug Type Exposure
• Small Molecules
• Biologics
• Medical Device Contract Manufacturing by Service Type Exposure
• Active Pharmaceutical Ingredient (API)
• Finished Drug Product
• Medical Device Contract Manufacturing by Forms Exposure
• Solids
• Liquids
• Medical Device Contract Manufacturing by Manufacturing Exposure
• Clinical Manufacturing
• Commercial Manufacturing
• Contract Development Manufacturing Organization Geography Exposure
• North America Contract Development Manufacturing Organization (CDMO) Market
• United States Contract Development Manufacturing Organization (CDMO) Market
• Canada Contract Development Manufacturing Organization (CDMO) Market
• Mexico Contract Development Manufacturing Organization (CDMO) Market
• Europe Contract Development Manufacturing Organization (CDMO) Market
• United Kingdom Contract Development Manufacturing Organization (CDMO) Market
• Germany Contract Development Manufacturing Organization (CDMO) Market
• France Contract Development Manufacturing Organization (CDMO) Market
• Italy Contract Development Manufacturing Organization (CDMO) Market
• Spain Contract Development Manufacturing Organization (CDMO) Market
• Rest of Europe Contract Development Manufacturing Organization (CDMO) Market
• Asia-Pacific Contract Development Manufacturing Organization (CDMO) Market
• China Contract Development Manufacturing Organization (CDMO) Market
• Japan Contract Development Manufacturing Organization (CDMO) Market
• India Contract Development Manufacturing Organization (CDMO) Market
• Australia Contract Development Manufacturing Organization (CDMO) Market
• South Korea Contract Development Manufacturing Organization (CDMO) Market
• Rest of Asia-Pacific Contract Development Manufacturing Organization (CDMO) Market
• Rest of the World Contract Development Manufacturing Organization (CDMO) Market
• South America Contract Development Manufacturing Organization (CDMO) Market
• Middle East Contract Development Manufacturing Organization (CDMO) Market
• Africa Contract Development Manufacturing Organization (CDMO) Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations and applications are profoundly transforming the contract development and manufacturing organization (CDMO) market by enhancing efficiency, precision, and speed across the entire drug development lifecycle. Artificial intelligence (AI) enables CDMOs to optimize complex processes such as molecule design, formulation development, and bioprocess optimization through predictive modeling and data-driven insights. Machine learning algorithms can analyze vast datasets from clinical trials, manufacturing processes, and quality control systems to identify patterns, reduce variability, and predict potential failures before they occur, thereby improving product quality and reducing time-to-market. Moreover, AI-driven automation in manufacturing facilitates real-time monitoring and adaptive control, ensuring greater consistency and regulatory compliance.

In research and development, generative AI tools are accelerating the identification of viable drug candidates and formulation stability testing, significantly shortening the discovery phase. Additionally, AI-powered digital twins and virtual process simulations allow CDMOs to evaluate production scenarios and scale-up processes more efficiently. Collectively, these innovations are enabling a shift from traditional trial-and-error approaches to intelligent, data-centric operations, positioning AI as a key enabler of next-generation pharmaceutical manufacturing and a strategic differentiator in the increasingly competitive CDMO landscape.

U.S. Tariff Impact Analysis on Contract Development Manufacturing Organization (CDMO) Market:

The imposition of U.S. tariffs on imported raw materials, intermediates, and pharmaceutical ingredients is having a multifaceted impact on the contract development and manufacturing organization (CDMO) market. These tariffs, particularly those targeting Chinese and European imports, have led to an increase in the overall cost of production for many U.S.-based CDMOs that rely heavily on global supply chains for active pharmaceutical ingredients (APIs), excipients, and specialized bioprocessing materials. Rising input costs have, in turn, placed pressure on profit margins and disrupted established supply networks, compelling several CDMOs to explore regional sourcing strategies or invest in localized manufacturing facilities to mitigate tariff-related risks.

However, the tariffs have also created new opportunities for domestic players by incentivizing the U.S. pharmaceutical and biotechnology companies to partner with local CDMOs instead of offshore providers. This has accelerated investment in advanced manufacturing technologies, such as continuous manufacturing and single-use bioreactor systems, to enhance cost efficiency and self-reliance. In essence, while tariffs have temporarily strained the global competitiveness of U.S. CDMOs due to higher input expenses, they have also reinforced the strategic importance of supply chain resilience and domestic capacity expansion within the American biopharmaceutical manufacturing ecosystem.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Contract Development Manufacturing Organization (CDMO) Market report study

• Market size analysis for the current Contract Development Manufacturing Organization (CDMO) Market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the Contract Development Manufacturing Organization (CDMO) Market.
• Various opportunities available for the other competitors in the Contract Development Manufacturing Organization (CDMO) Market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current Contract Development Manufacturing Organization (CDMO) Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the Contract Development Manufacturing Organization (CDMO) Market growth in the future?

Frequently Asked Questions for the Contract Development Manufacturing Organization (CDMO) Market

1. What is the growth rate of the contract development manufacturing organization (CDMO) market?

• The contract development manufacturing organization (CDMO) market is estimated to grow at a CAGR of 7.25% during the forecast period from 2026 to 2034.

2. What is the market for medical device contract manufacturing?

• The global contract development manufacturing organization (CDMO) market is expected to increase from USD 233.71 billion in 2025 to USD 407.09 billion by 2034, reflecting strong and sustained growth.

3. Which region has the highest share in the contract development manufacturing organization (CDMO) market?

• North America is expected to dominate the overall contract development manufacturing organization market due to the strong pharmaceutical innovation, advanced biotechnology infrastructure, and a well-established regulatory environment. The region's growing burden of chronic diseases such as cancer and cardiovascular disorders is fueling demand for complex therapeutics, prompting greater outsourcing of drug development and manufacturing to specialized CDMOs. Continuous investments in biologics, biosimilars, and advanced manufacturing technologies, along with a surge in personalized medicine initiatives, are further strengthening market growth. Supported by robust R&D capabilities, favorable FDA regulations, and active collaborations among industry players.

4. What are the drivers for the contract development manufacturing organization (CDMO) market?

• The growth of the global contract development and manufacturing organization (CDMO) market is driven by the rising prevalence of chronic diseases, the rapid expansion of biologics and biosimilar production, and increasing strategic collaborations and mergers among key players. The growing burden of conditions such as cancer, diabetes, and cardiovascular disorders is prompting pharmaceutical and biotechnology companies to outsource drug development and manufacturing to CDMOs for their expertise, scalability, and cost efficiency. Meanwhile, the surge in biologics and biosimilars is creating new opportunities for CDMOs with advanced bioprocessing and regulatory capabilities. Additionally, ongoing partnerships and M&A activities are enabling companies to expand service offerings, strengthen global presence, and enhance technological competitiveness, fostering a more integrated and innovation-driven CDMO market.

5. Who are the key players operating in the contract development manufacturing organization (CDMO) market?

• Some of the key market players operating in the contract development manufacturing organization (CDMO) market include Catalent Inc., Thermo Fisher Scientific Inc., The Lubrizol Corporation, Recipharm (EQT), Cambrex Corporation, Merck & Co. Inc., AGC Biologics, Nerpharma S.r.l., Danaher Corporation, EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Revvity Inc., WuXi Biologics, Laboratoire Elaiapharm, and others.